IP Library Granted Patent US 12680107
Granted Patent B2
US 12680107 · App. 18/320,789 · Granted Jul 14, 2026

Non-human animals comprising a humanized ASGR1 locus

Inventors: Alexander O. Mujica (Elmsford, NY); Viktoria Gusarova (Pleasantville, NY); Cheng Wang (Beijing, CN); Christos Kyratsous (Irvington, NY); Terra Potocky (Dobbs Ferry, NY); Katherine Cygnar (New York, NY); Joel H. Martin (Putnam Valley, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C12N15/8509A01K67/0278C07K14/7056C12N15/85A01K2207/15A01K2217/072A01K2227/105C12N5/0608C12N5/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12680107
App. No.
18/320,789
Granted
Jul 14, 2026
Kind
B2
Abstract

Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.

Claims (6)

1 . A nucleic acid comprising a first nucleic acid sequence that encodes the amino acid sequence as set forth in SEQ ID NO: 3, wherein the nucleic acid further comprises a second nucleic acid sequence selected from the group consisting of the nucleic acid sequence as set forth in SEQ ID NO: 18, the nucleic acid sequence as set forth in SEQ ID NO: 19, the nucleic acid sequence as set forth in SEQ ID NO: 20, and the nucleic acid sequence as set forth in SEQ ID NO:23.

2 . The nucleic acid of claim 1 , comprising the nucleic acid sequence as set forth in SEQ ID NO:24.

3 . The nucleic acid of claim 1 , comprising the nucleic acid sequence as set forth in SEQ ID NO: 21.

4 . A targeting vector comprising the nucleic acid of claim 1 flanked by 5′ and 3′ homology arms corresponding to 5′ and 3′ target sites within an endogenous mouse Asgr1 locus.

5 . A targeting vector comprising the nucleic acid of claim 2 flanked by 5′ and 3′ homology arms corresponding to 5′ and 3′ target sites within an endogenous mouse Asgr1 locus.

6 . A targeting vector comprising the nucleic acid of claim 3 flanked by 5′ and 3′ homology arms corresponding to 5′ and 3′ target sites within an endogenous mouse Asgr1 locus.